Dennis Yang1, Roxana M Coman1, Michel Kahaleh2, Irving Waxman3, Andrew Y Wang4, Amrita Sethi5, Ashish R Shah5, Peter V Draganov6. 1. Division of Gastroenterology, Hepatology and Nutrition, College of Medicine, University of Florida, Gainesville, Florida, USA. 2. Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, New York, USA. 3. Center for Endoscopic Research and Therapeutics, The University of Chicago School of Medicine, Chicago, Illinois, USA. 4. Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, Virginia, USA. 5. Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, New York, USA. 6. Division of Gastroenterology, Hepatology and Nutrition, College of Medicine, University of Florida, Gainesville, Florida, USA. Electronic address: peter.draganov@medicine.ufl.edu.
Abstract
BACKGROUND AND AIMS: The role of endoscopic submucosal dissection (ESD) in Barrett's early neoplasia is not well defined, with most studies originating from Asia and Europe. We aimed to assess the efficacy, safety, and results of ESD in Barrett's esophagus (BE) with high-grade dysplasia (HGD) and early adenocarcinoma (EAC) across centers in the United States. METHODS: Multicenter retrospective analysis on 46 patients with BE who underwent ESD for BE-HGD or EAC, or both, between January 2010 and April 2015. The primary endpoint was the rate of en bloc resection. Secondary aims included rate of R0 (complete) and curative resection, a comparison of pre- and post-ESD histology, procedure-related adverse events, and rate of remission at follow-up. RESULTS: Median age was 69 years (range, 42-82 years). The median resected specimen size was 45 mm (range, 13-125 mm). En bloc and curative resection rates were 96% (44/46) and 70% (32/46), respectively. Most lesions (11/20; 55%) diagnosed as BE-HGD on biopsy were upstaged to intramucosal or invasive EAC on post-ESD histopathology. There were 4 early (<48 hours) adverse events (3 bleeding and 1 perforation), and all were treated endoscopically. Seven patients (15%) developed esophageal strictures that were managed endoscopically. Complete remission of BE neoplasia was found in 100% (32/32) of patients with curative resection at median follow-up of 11 months (range, 2-25 months). CONCLUSIONS: This is the largest multicenter series of ESD for early neoplastic BE from the United States. ESD appears to be safe and effective, with high en bloc and curative resection rates in the treatment of early BE neoplasia.
BACKGROUND AND AIMS: The role of endoscopic submucosal dissection (ESD) in Barrett's early neoplasia is not well defined, with most studies originating from Asia and Europe. We aimed to assess the efficacy, safety, and results of ESD in Barrett's esophagus (BE) with high-grade dysplasia (HGD) and early adenocarcinoma (EAC) across centers in the United States. METHODS: Multicenter retrospective analysis on 46 patients with BE who underwent ESD for BE-HGD or EAC, or both, between January 2010 and April 2015. The primary endpoint was the rate of en bloc resection. Secondary aims included rate of R0 (complete) and curative resection, a comparison of pre- and post-ESD histology, procedure-related adverse events, and rate of remission at follow-up. RESULTS: Median age was 69 years (range, 42-82 years). The median resected specimen size was 45 mm (range, 13-125 mm). En bloc and curative resection rates were 96% (44/46) and 70% (32/46), respectively. Most lesions (11/20; 55%) diagnosed as BE-HGD on biopsy were upstaged to intramucosal or invasive EAC on post-ESD histopathology. There were 4 early (<48 hours) adverse events (3 bleeding and 1 perforation), and all were treated endoscopically. Seven patients (15%) developed esophageal strictures that were managed endoscopically. Complete remission of BE neoplasia was found in 100% (32/32) of patients with curative resection at median follow-up of 11 months (range, 2-25 months). CONCLUSIONS: This is the largest multicenter series of ESD for early neoplastic BE from the United States. ESD appears to be safe and effective, with high en bloc and curative resection rates in the treatment of early BE neoplasia.
Authors: Masami Omae; Hannes Hagström; Nelson Ndegwa; Michael Vieth; Naining Wang; Miroslav Vujasinovic; Francisco Baldaque-Silva Journal: Endosc Int Open Date: 2021-04-22
Authors: Peter V Draganov; Hiroyuki Aihara; Michael S Karasik; Saowanee Ngamruengphong; Abdul Aziz Aadam; Mohamed O Othman; Neil Sharma; Ian S Grimm; Alaa Rostom; B Joseph Elmunzer; Salmaan A Jawaid; Donevan Westerveld; Yaseen B Perbtani; Brenda J Hoffman; Alexander Schlachterman; Amanda Siegel; Roxana M Coman; Andrew Y Wang; Dennis Yang Journal: Gastroenterology Date: 2021-02-19 Impact factor: 22.682
Authors: Ling Li; Mohamad I Itani; Kevan J Salimian; Yue Li; Olaya Brewer Gutierrez; Haijie Hu; George Fayad; Jean A Donet; Min Kyung Joo; Laura M Ensign; Vivek Kumbhari; Florin M Selaru Journal: Sci Rep Date: 2021-06-25 Impact factor: 4.379